Studies in animal model on the thrombogenicity of a new prothrombin complex concentrate from Argentina.

BERNARDI, ME, VITALI, MS, MOYA, C, GUGLIELMONE, HA, CUADRA, GR.

TRANSFUSION MEDICINE

Blackwell Scientific Publications

Lugar: Oxford, England; Año: 2007 vol. 17 p. 420 - 420

0958-7578

font face="AdvTimes" size="2"> In summary, based on the encouraging data obtained from these animal experiments, it seems apparent that our PCC meets the requirements of a low-thrombogenicity product. A clinical study in patients with defects of vitamin K-dependent factors is in progress using PCC formulated with no more than 05 IU heparin IU F IX21 according to European Pharmacopoeia.21 according to European Pharmacopoeia.